Literature DB >> 24381658

Current and future options in the management and treatment of uterine sarcoma.

Khalid El-Khalfaoui1, Andreas du Bois2, Florian Heitz2, Christian Kurzeder2, Jalid Sehouli3, Philipp Harter2.   

Abstract

Uterine sarcomas are rare aggressive mesenchymal tumours with limited prognosis. They encompass various histological subtypes such leiomyosarcoma, endometrial stromal sarcoma and undifferentiated sarcomas with different surgical and medical strategies. Current evidence of surgery, adjuvant and palliative therapy is reported.

Entities:  

Keywords:  chemotherapy; endometrial stromal sarcoma; surgery; uterine leiomyosarcoma; uterine sarcoma

Year:  2014        PMID： 24381658      PMCID： PMC3866995          DOI： 10.1177/1758834013513314

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  55 in total

1.  Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.

Authors:  Mario M Leitao; Oliver Zivanovic; Dennis S Chi; Martee L Hensley; Roisin O'Cearbhaill; Robert A Soslow; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2012-02-21       Impact factor: 5.482

2.  The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.

Authors:  Jeong-Yeol Park; Sun-Kyung Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  Gynecol Oncol       Date:  2011-05-12       Impact factor: 5.482

3.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

Authors:  Xavier García-Del-Muro; Antonio López-Pousa; Joan Maurel; Javier Martín; Javier Martínez-Trufero; Antonio Casado; Auxiliadora Gómez-España; Joaquín Fra; Josefina Cruz; Andrés Poveda; Andrés Meana; Carlos Pericay; Ricardo Cubedo; Jordi Rubió; Ana De Juan; Nuria Laínez; Juan Antonio Carrasco; Raquel de Andrés; José M Buesa
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

4.  Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Authors:  Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

5.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

Authors:  G A Omura; J A Blessing; F Major; S Lifshitz; C E Ehrlich; C Mangan; J Beecham; R Park; S Silverberg
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

6.  Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Authors:  Martee L Hensley; J Kyle Wathen; Robert G Maki; Dejka M Araujo; Gregory Sutton; Dennis A Priebat; Suzanne George; Robert A Soslow; Laurence H Baker
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

7.  Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.

Authors:  B A Goff; L W Rice; D Fleischhacker; H G Muntz; S S Falkenberry; N Nikrui; A F Fuller
Journal:  Gynecol Oncol       Date:  1993-07       Impact factor: 5.482

8.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Authors:  George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

Review 9.  The management of patients with uterine sarcoma: a debated clinical challenge.

Authors:  Angiolo Gadducci; Stefania Cosio; Antonella Romanini; Andrea Riccardo Genazzani
Journal:  Crit Rev Oncol Hematol       Date:  2007-08-13       Impact factor: 6.312

10.  Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases.

Authors:  Tahereh Ashraf-Ganjoei; Nadereh Behtash; Mamak Shariat; Asamosadat Mosavi
Journal:  World J Surg Oncol       Date:  2006-08-09       Impact factor: 2.754
View more
  5 in total

1.  The prognosis factor of adjuvant radiation therapy after surgery in uterine sarcomas.

Authors:  Hai-Ling Hou; Mao-Bin Meng; Xiu-Li Chen; Lu-Jun Zhao; Li Zhu; Bai-Lin Zhang; Ping Wang
Journal:  Onco Targets Ther       Date:  2015-08-28       Impact factor: 4.147

2.  Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.

Authors:  Alberto Bongiovanni; Nada Riva; Marianna Ricci; Laura Mercatali; Chiara Liverani; Federico La Manna; Alessandro De Vita; Davide Cavaliere; Federica Pieri; Devil Oboldi; Giorgio Maria Verdecchia; Dino Amadori; Toni Ibrahim
Journal:  BMC Cancer       Date:  2015-12-22       Impact factor: 4.430

3.  Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.

Authors:  Hyun Jun Kim; Youjin Kim; Su Jin Lee; Jeeyun Lee; Se Hoon Park
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

4.  Prolonged response to exemestane following multiple surgical resections and hormonal therapies in a patient with recurrent endometrial stromal sarcoma.

Authors:  Heather Wolfe; Kristen Bunch; Michael Stany
Journal:  Gynecol Oncol Rep       Date:  2015-08-07

5.  Isobolographic Analysis Demonstrates the Additive and Synergistic Effects of Gemcitabine Combined with Fucoidan in Uterine Sarcomas and Carcinosarcoma Cells.

Authors:  Marcin Bobiński; Karolina Okła; Jarogniew Łuszczki; Wiesława Bednarek; Anna Wawruszak; Gema Moreno-Bueno; Magdalena Dmoszyńska-Graniczka; Rafał Tarkowski; Jan Kotarski
Journal:  Cancers (Basel)       Date:  2019-12-31       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.